ArticleInternational journal of molecular sciences2026
Retrieval-Guided Transfer Learning for Low-Resource Ebola Drug-Target Affinity Prediction.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-target affinity (DTA) prediction plays an important role in computational drug discovery; however, its application to emerging infectious diseases such as Ebola remains challenging because of the limited availability of experimentally measured affinity data. To address this low-resource setting, we propose a retrieval-guided transfer-learning framework that leverages BindingDB interactions to improve Ebola DTA prediction. The framework uses a two-stage strategy. In Stage I, source interactions are selected using random sampling, compound-similarity retrieval, protein-similarity retrieval, or hybrid compound-protein retrieval at source-data budgets of 50,000 and 300,000 interactions and combined with Ebola training data to learn transferable representations. In Stage II, the pretrained compound and protein encoders are frozen, while the prediction layers are adapted to the Ebola domain. The framework was implemented with DeepDTA and GraphDTA and evaluated across five random seeds using a scaffold-based split, with conventional machine-learning models and single-stage deep learning as baselines. The best overall configuration, GraphDTA with protein-similarity-guided retrieval at the 50,000-interaction budget, achieved RMSE =0.5498±0.1073, R2=0.8809±0.0452, and Pearson =0.9395±0.0237, outperforming the strongest conventional machine-learning model (Extra Trees, RMSE =0.6065±0.0642) and single-stage GraphDTA (RMSE =0.6533±0.0752). Across both source-data budgets and both DTA backbones, all targeted retrieval configurations achieved lower mean RMSE than their corresponding random-retrieval configurations. At the 50,000-interaction budget, matched seed-wise analysis further showed consistent improvements for protein-guided retrieval across all five seeds for both backbones. Retrieval characterization showed stronger target-domain similarity and substantially lower cross-strategy overlap at 50,000 than at 300,000 interactions, while post hoc sequence analysis independently confirmed enrichment of sequence-level relatedness with protein-guided retrieval. Increasing the source-data budget from 50,000 to 300,000 did not uniformly improve predictive performance, indicating that source-data relevance and retrieval selectivity should be considered jointly with source-data quantity. Finally, virtual-screening and approved-drug repurposing case studies across six Ebola virus targets demonstrate the use of the framework for computational prioritization of compound-target hypotheses. Overall, the findings support relevance-guided source-data selection as an effective strategy for transfer learning in low-resource DTA prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.